Wellington Management Group LLP Sells 16,541,586 Shares of Pfizer Inc. $PFE

Wellington Management Group LLP cut its position in Pfizer Inc. (NYSE:PFE) by 21.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,461,953 shares of the biopharmaceutical company’s stock after selling 16,541,586 shares during the period. Wellington Management Group LLP owned about 1.06% of Pfizer worth $1,540,571,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Peak Asset Management LLC increased its stake in Pfizer by 1.4% in the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after buying an additional 402 shares in the last quarter. Community Bank & Trust Waco Texas lifted its position in shares of Pfizer by 0.6% in the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after acquiring an additional 412 shares in the last quarter. CVA Family Office LLC boosted its stake in shares of Pfizer by 3.3% in the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 413 shares during the period. Boltwood Capital Management grew its position in shares of Pfizer by 0.7% during the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after purchasing an additional 420 shares in the last quarter. Finally, Beverly Hills Private Wealth LLC raised its stake in Pfizer by 1.5% during the 3rd quarter. Beverly Hills Private Wealth LLC now owns 27,955 shares of the biopharmaceutical company’s stock valued at $712,000 after purchasing an additional 421 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP?1 weight?management drug Xianweiying, opening a large, fast?growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early?stage oncology candidate (PF?07994525), expanding its cancer pipeline and showing continued R&D momentum in higher?value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long?acting growth?hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia?Pacific growth), useful for medium?term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long?term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI?driven drug discovery; this supports long?run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post?COVID revenue normalization and drug?pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share?price base rather than improving top?line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short?term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Pfizer Stock Performance

NYSE:PFE opened at $26.60 on Friday. The company has a market cap of $151.23 billion, a price-to-earnings ratio of 19.56 and a beta of 0.47. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The stock’s 50 day simple moving average is $26.50 and its two-hundred day simple moving average is $25.52. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the prior year, the company earned $0.63 EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on PFE shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a research report on Monday, March 2nd. Bank of America lowered their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 target price on shares of Pfizer in a research note on Monday. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.05.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.